NDAORALFOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENBRITIN is an oral suspension formulation of ampicillin/ampicillin trihydrate, a beta-lactam antibiotic used to treat bacterial infections across multiple indications. The drug works by inhibiting bacterial cell wall synthesis. It is currently in pre-launch stage under NDA sponsorship by Thayer Medical.
Pre-Launch
Pre-launch stage indicates limited immediate commercial infrastructure; team building and launch preparation activities are likely underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PENBRITIN in pre-launch phase offers opportunity to build a commercial franchise from inception and establish market positioning for an oral antibiotic suspension. Career impact depends on successful NDA approval and subsequent market adoption; roles focus on launch preparation, market access, and field execution.
Brand ManagerField Sales Representative
Worked on PENBRITIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.